A new drug that delivers copper to the brain could significantly reduce the buildup of toxic proteins associated with Alzheimer’s disease and improve long-term spatial memory, according to groundbreaking research findings published in the American Chemical Society’s Chemical Neuroscience journal that show promising results for a new therapeutic avenue targeting neurovascular dysfunction.
The study reveals that a copper-containing compound called ‘Cu(ATSM)’ repairs a vital waste-clearing pump in mouse models with Alzheimer’s disease, potentially unlocking a new treatment approach for neurovascular dysfunction by targeting the brain’s blood vessels to lower toxic protein levels and generate behavioural benefits.
Lead author Jae Pyun from the drug delivery, disposition and dynamics theme at Monash Institute of Pharmaceutical Sciences (MIPS) said the treatment successfully engages the brain’s blood vessels to lower toxic protein levels resulting in behavioral benefits, marking the first study to show that the copper-containing compound can increase the abundance of P-gp clearance pumps in an Alzheimer’s model by 24.1 percent, effectively linking the repair of the blood-brain barrier to a reduction in toxic proteins and improved cognitive function.
Pyun explained that by improving the pumps, the brain can finally clear out the trapped waste, and over 56 days of treatment, toxic amyloid-beta was reduced by 42 per cent while spatial learning improved by nearly 44 per cent.
The authors wrote that Cu(ATSM) administered at 30 milligrams per kilogram per day for 56 days, restored brain microvascular P-gp abundance by 24.1 percent and copper concentrations by 229.8 percent, while significantly reducing brain cortical concentrations of human amyloid protein by 42.1 percent in diseased mice.
Importantly, Cu(ATSM) treatment led to significantly improved 43.8 percent learning and long-term spatial memory in diseased mice, demonstrating the compound’s potential as a therapeutic intervention for Alzheimer’s disease.
The findings build on growing research into neurovascular dysfunction as a key factor in Alzheimer’s pathology, with the copper-containing compound representing a novel approach that repairs the brain’s natural waste-clearing mechanisms rather than simply targeting toxic proteins directly.
This research comes at a critical time when new Alzheimer’s treatments are arriving in India, including donanemab, which aims to slow the disease’s progression by clearing brain plaques, though the copper-containing drug offers a different therapeutic mechanism focused on restoring the brain’s natural clearance pumps.
Alzheimer’s disease continues to be a major global health challenge, with toxic protein buildup in the brain being a hallmark of the condition that disrupts normal cognitive function and leads to progressive memory loss and confusion.
The study’s success in mouse models raises hopes for potential future human trials, though researchers emphasize that significant additional work is needed to translate these promising animal findings into clinical treatments for Alzheimer’s patients.
The copper-delivery approach represents a departure from traditional Alzheimer’s therapies that focus on directly reducing amyloid-beta plaques, instead working to enhance the brain’s innate ability to clear toxic waste through improved P-gp pump function.
Findings from Monash University and the American Chemical Society suggest this could be a meaningful step forward in developing treatments for neurovascular dysfunction, which has been increasingly recognized as a critical component of Alzheimer’s disease progression and cognitive decline.
